Kido K, et al. - Researchers analyzed relevant studies identified from the MEDLINE, Embase, Google Scholar, Web of Science, and Cochrane Library databases, to compare direct oral anticoagulants (DOACs) with warfarin in morbidly obese patients suffering from atrial fibrillation (AF) as well as to optimize an anticoagulation therapy in the population. They performed a meta-analysis including 5 studies for the event rate of stroke or systemic embolism (SE) and 4 studies for major bleeding. The DOAC and warfarin groups did not have statistically significant difference in terms of stroke or SE event rate. A significant link of DOAC use with a lower major bleeding event rate, vs the warfarin group, was revealed. Based on these findings, experts recommended considering DOACs as an oral anticoagulant to prevent stroke or SE in morbidly obese patients experiencing AF.